FMR LLC's Schedule 13G Filing for Amylyx Pharmaceuticals Inc

FMR LLC filed a Schedule 13G with the SEC, disclosing its ownership of 11,379,207 shares of common stock in Amylyx Pharmaceuticals Inc, representing 10.7% of the total outstanding shares. The filing indicates that FMR LLC has sole voting power over 11,361,910 shares and sole dispositive power over all 11,379,207 shares. The filing also includes Abigail P. Johnson as a reporting person, who has sole dispositive power over the same number of shares. The filing is made under Rule 13d-1(b) and includes certifications that the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control of the issuer.